# Protocol and Demographics of the RELY-CD Study: Assessing Long-Term Clinical Response to Botulinum Neurotoxin in Cervical Dystonia

## TL;DR

This study examines long-term treatment outcomes of botulinum toxin for cervical dystonia in real-world settings over up to 10 years.

## Contribution

The study introduces a novel dose–effect parameter (DEff) to assess treatment adjustments and identify partial failures.

## Key findings

- The DEff parameter enabled quantification of dose adjustments and clinical outcomes.
- The study highlights differences in treatment outcomes between complex-free and complex-containing botulinum toxin formulations.
- It provides insights into long-term treatment resistance and clinical response patterns.

## Abstract

The RELY-CD study investigated the long-term clinical response to botulinum neurotoxin type A in cervical dystonia within a multicenter, real-world setting. This retrospective study focused on patients treated with complex-free (incobotulinumtoxinA) and complex-containing (onabotulinumtoxinA and abobotulinumtoxinA) BoNT/A formulations over an up to 10-year period. The novel dose–effect parameter “DEff” was introduced to quantify the relationship between dose adjustments and clinical outcomes, enabling the identification of partial treatment failures. The primary endpoint was a comparison of a clinically meaningful worsening in DEff in treatment year 7 compared to year 2 between complex-free and complex-containing botulinum neurotoxin type A. The RELY-CD study provides unique insights into long-term treatment patterns, clinical resistance phenomena, and the implications of formulation differences on treatment outcomes, addressing a critical gap in the literature on real-world botulinum neurotoxin type A application. The study methodology, including the definition and calculation of the novel DEff, as well as clinical baseline characteristics, are presented.